Clinical Trial Goal
To find out:
- The highest dose of ulixertinib that's safe to give with ruxolitinib
- If the combination of ruxolitinib and ulixertinib is safe and works well to treat myelofibrosis
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following diseases:
- Pre-fibrotic primary myelofibrosis
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have been treated with ruxolitinib for at least 3 months
- Are not eligible for allogeneic (cells from a donor) blood or marrow transplant (BMT). Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells. This means the drug tries to stop certain T-cell signals that can lead to tissue damage.
Ulixertinib is a small molecule inhibitor that blocks ERK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Ulixertinib is a small molecule inhibitor that blocks ERK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Ruxolitinib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Ulixertinib – A pill that you take by mouth 2 times each day
You'll have biopsies to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved Ulixertinib.
Locations
Sponsors
collaborator: BioMed Valley Discoveries, Inc, collaborator: Incyte Corporation, lead: Memorial Sloan Kettering Cancer Center
